Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft

PHASE4RecruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

December 1, 2029

Study Completion Date

December 1, 2029

Conditions

Epstein-Barr Virus Infections

Interventions

DRUG

Rituximab

One single dose of rituximab intravenously (IV)

OTHER

control group

No treatment

Trial Locations (1)

RECRUITING

Les Hôpitaux Universitaires de Strasbourg, Strasbourg

All Listed Sponsors

lead

University Hospital, Strasbourg, France

OTHER